Custodiol-N
Phase 2Small molecule
Custodiol-N is one of 38 small molecule programs targeting Coronary Artery Bypass. It is currently in Phase 2.
1
Indications
5
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
148 competitors in Coronary Artery Bypass
#DrugCompanyPhaseTrials
1Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Aggrastat
MMedicure
Phase 3
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Intralipid
AstraZenecaPhase 3
Glargine Insulin
AstraZenecaPhase 3
Low-Dose Aspirin
PPharmaEssentia Japan K.K.
Phase 3
Acadesine
Merck & Co.Phase 3
Hypertonic Lactate
IInnogene Kalbiotech Pte. Ltd
Phase 3
Glulisine
EEmory University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart Transplantation2 trials
Transplantation1 trial
Coronary Artery Bypass1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Custodiol-N. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDr. F. Köhler Chemie GmbH